Scinai Immunotherapeutics Ltd. Announces Peer-Reviewed Data Supporting PC111 as Potential Disease Modifier

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced the publication of a peer-reviewed article in the Journal of Dermatological Treatment, showcasing the disease-modifying potential of PC111, a first-in-class human anti-Fas Ligand monoclonal antibody. The study's findings demonstrate PC111's ability to prevent blister formation in humanized models of pemphigus by targeting soluble Fas Ligand, presenting a novel, non-immunosuppressive approach to treatment. Additionally, the data suggests potential applications in treating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), a severe and life-threatening dermatological condition.

Amir Reichman, CEO of Scinai Immunotherapeutics, emphasized that these findings underscore PC111's potential to revolutionize treatment options for these conditions, which currently have high unmet medical needs, and to deliver significant value to both patients and shareholders. The publication of this data marks a critical step forward in the development of PC111 as a therapeutic option, reinforcing its promise in addressing complex dermatological diseases.

For further details on the study and its implications, the full press release can be accessed here.